Amplia Therapeutics Limited

ASX (AUD): Amplia Therapeutics Limited (ATX)

Last Price

0.099

Today's Change

-0.001 (1.00%)

Day's Change

0.096 - 0.105

Trading Volume

1,814,297

Overview

Market Cap

31 Million

Shares Outstanding

317 Million

Avg Volume

911,225

Avg Price (50 Days)

0.13

Avg Price (200 Days)

0.09

PE Ratio

-4.95

EPS

-0.02

Earnings Announcement

18-Nov-2024

Previous Close

0.10

Open

0.10

Day's Range

0.096 - 0.105

Year Range

0.055 - 0.18

Trading Volume

1,827,367

Price Change Highlight

1 Day Change

-1.00%

5 Day Change

4.21%

1 Month Change

-38.12%

3 Month Change

-26.67%

6 Month Change

73.68%

Ytd Change

23.75%

1 Year Change

34.03%

3 Year Change

-46.49%

5 Year Change

35.21%

10 Year Change

-93.73%

Max Change

-94.38%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment